Europe Set To Approve New Self-Amplifying RNA "Vaccine" Tech That May "Vaccinate" Others Via Shedding

On Thursday the European Union’s medicine committee recommended marketing authorization of a novel exotic technology referred to as ‘self-amplifying RNA vaccines’ or ‘replicon vaccines’. Called Kostaive, it is reportedly for ‘protection’ against Covid. In October Japan became the first country on earth to begin injecting their population with the new shot.

“On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults,” the European Medicines Agency said Thursday.

Unlike the notorious mRNA gene therapy injections used to ‘combat’ Covid, which make the vaccinated individual’s body produce an antigen (the spike protein in the case of the Covid shots) the new saRNA vaccines go a step further, making the body replicate the replication mechanism itself. Traditional (real) vaccines contain the antigen, which is intended to illicit an immune response in the body, unlike mRNA vaccines which make the body itself produce the antigen, which is then intended to illicit an immune response. Traditional vaccines also contain neurotoxins such as aluminum as an adjuvant (to agitate the immune system into action) and mercury as a preservative.

“Kostaive will be available as a powder for dispersion for injection. Kostaive is a RNA-based COVID-19 vaccine (ATC code: J07BN01). It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. Once administered into a muscle, the replicase protein makes more copies of the mRNA, which the cell can use to make more spike protein. Vaccination with Kostaive induces the production of neutralising antibodies and a cellular immune response targeting the spike protein, which helps protect people against COVID-19,” the European Medicines Agency said Thursday.

The new shot triggers side effects 90 percent of the time.

“During the clinical trials for Kostaive, five deaths were reported among participants in the phase 3b study. Across study phases 1, 2, and 3a combined, 90 percent of injected participants experienced adverse events, with 74.5 percent reporting systemic reactions and 15.2 percent requiring medical attention after the first dose. Notably, many of the study authors are full-time employees of Arcturus Therapeutics, raising concerns about bias in their conclusions,” Lifesite News said Tuesday.

The new technology has been labeled as intrinsically dangerous and even as a bioweapon by some, sparking fears of the vaccine itself spreading to the non-vaccinated population, a step far beyond vaccine shedding.

“The man-made genes in the replicon vaccines, if introduced into humans, are likely to spread not only to other humans but also to other species,” The Expose said in September.